Wainwright

Ditching the young entrepreneur myth: research shows over-50s are the more radical innovators

Retrieved on: 
Wednesday, August 9, 2023

In our study published in July, we provide evidence that older entrepreneurs have a lot to offer.

Key Points: 
  • In our study published in July, we provide evidence that older entrepreneurs have a lot to offer.
  • Our findings show that those who start businesses later in life (50 years old and above) are more likely to bring radical innovations to the market than younger business owners.
  • Breaking the myth of the young entrepreneur
    Our findings challenge the dominant stereotype that older founders are not very innovative.
  • Currently, these workers may leave their jobs and become entrepreneurs to pursue radically new and commercially successful ideas.

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Wednesday, May 10, 2023

KANSAS CITY, Kan., May 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the three months ended March 31, 2023, as well as a clinical and business update. Among other highlights, the Company announced it has obtained an additional $3 million of debt financing, successfully completed the transfer of its proprietary PTR™ manufacturing processes to Societal CDMO, Inc. (Societal) and entered into a joint commercialization agreement with Indegene to provide commercial support for CTx-1301 upon approval from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • CTx-1301: Cingulate advanced its clinical program for CTx-1301 on the streamlined approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
  • Assuming positive clinical results from the Phase 3 trials, Cingulate plans to submit the NDA for CTx-1301 in mid-2024 under the Section 505(b)(2) pathway.
  • Cash Position: As of March 31, 2023, Cingulate had $1.7 million in cash and cash equivalents.
  • This decrease in manufacturing expense was slightly offset by an increase in clinical and regulatory costs as we initiated a Phase 3 clinical trial for CTx-1301 in the first quarter of 2023.

Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Friday, March 10, 2023

KANSAS CITY, Kan., March 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three and 12 months ended December 31, 2022, and provided a clinical and business update. Highlights include multiple clinical updates on CTx-1301, the Company’s lead candidate being investigated as a true, once-daily treatment for attention deficit/hyperactivity disorder (ADHD).

Key Points: 
  • Highlights include multiple clinical updates on CTx-1301, the Company’s lead candidate being investigated as a true, once-daily treatment for attention deficit/hyperactivity disorder (ADHD).
  • Dr. Childress has conducted over 180 clinical studies and is considered a preeminent global ADHD expert.
  • CTx-1301: Cingulate advanced its clinical program for CTx-1301 on the streamlined approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
  • In addition, the Company’s manufacturing costs increased in 2022 relating to the production of clinical supply for Phase 3 trials of CTx-1301.

Symposium at the Driehaus Museum Will Bring Together Noteworthy Speakers to Address "The Art of Architecture: Perspectives on Sullivan & Nickel"

Retrieved on: 
Friday, September 23, 2022

The event will be held Saturday, October 22, from 10:00 am to 6:00 pm.

Key Points: 
  • The event will be held Saturday, October 22, from 10:00 am to 6:00 pm.
  • All tickets include free admission to the Museum between October 21-23.
  • David Van Zanten, highlighting Sullivan's developing use of ornamentation, culminating in his design for the Wainwright Building (St Louis, 1890-91).
  • Alison Fisher, the Harold and Margot Schiff Curator of Architecture and Design at the Art Institute of Chicago, moderates one session.

HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments‎ and the Issuance of Shares for Debt

Retrieved on: 
Thursday, August 18, 2022

The Company intends to use the proceeds from the close of the First Tranche for general working capital purposes.

Key Points: 
  • The Company intends to use the proceeds from the close of the First Tranche for general working capital purposes.
  • The Company has applied to list the Conversion Shares, the Warrant Shares, the Debt Shares, and the Compensation Shares on the Canadian Securities Exchange (the "CSE").
  • The New Warrants will be subject to a four-month and one day hold period under applicable securities laws in Canada.
  • Prior to closing of the first Tranche, the Subscriber did not beneficially own or control any securities of the Company.

CEO Brian Wainwright Wins Vistage 2021 Leadership Award

Retrieved on: 
Tuesday, December 28, 2021

MANAHAWKIN, N.J., Dec. 28, 2021 /PRNewswire/ -- Brian Wainwright, CEO and Founder of The Wireless Experience, has won the Tri-State's 2021 Vistage Leadership Award.

Key Points: 
  • MANAHAWKIN, N.J., Dec. 28, 2021 /PRNewswire/ -- Brian Wainwright, CEO and Founder of The Wireless Experience, has won the Tri-State's 2021 Vistage Leadership Award.
  • Created by Vistage, the world's largest CEO coaching and peer advisory organization for small and midsize businesses, the award celebrates a member's enduring excellence in leadership, recognizing the discernible impact they've had on their business, Vistage group and community.
  • Wainwright launched The Wireless Experience in 1997 and has led the company from mom-and-pop to top-rated East Coast AT&T retailer, expanding to 91 locations across six states in 2021 and earning five-time certification as a Great Place to Work.
  • "This recognition means a lot because it comes from Vistage," said Wainwright.

Appili Therapeutics to Present at the 2021 VIRTUAL H.C. Wainwright BioConnect Conference

Retrieved on: 
Wednesday, January 6, 2021

Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, announced today that Appilis CEO Dr. Armand Balboni will participate in HC Wainwrights Bioconnect 2021 investor event.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, announced today that Appilis CEO Dr. Armand Balboni will participate in HC Wainwrights Bioconnect 2021 investor event.
  • The virtual conference takes place from January 11 14, 2021.
  • Presentation details are as follows:
    Type: Pre-recorded Company Presentation from Dr. Balboni
    This is the inaugural virtual H.C. Wainwright BioConnect Conference.
  • H.C. Wainwright is hosting the event to provide clients with a forum to virtually present to investors during the timeframe of the JP Morgan Healthcare Conference.

BIOLASE To Present At The H.C. Wainwright's BIOCONNECT 2021 Investor Conference

Retrieved on: 
Tuesday, January 5, 2021

ET on January 11th, and can be accessed in the investor relations section of BIOLASE's website at www.biolase.com .

Key Points: 
  • ET on January 11th, and can be accessed in the investor relations section of BIOLASE's website at www.biolase.com .
  • To request a meeting please contact your H.C. Wainwright representative or BIOLASE's investor relations firm at [email protected] .
  • BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.
  • BIOLASE, Waterlase and Waterlase iPlus are registered trademarks ofBIOLASE, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/biolase-to-present-at-the-hc-wai...

CECO Environmental to Present at the 22nd Annual H.C. Wainwright Global Investment Conference on September 14th

Retrieved on: 
Tuesday, September 1, 2020

DALLAS, Sept. 1, 2020 /PRNewswire/ -- CECO Environmental Corp. (Nasdaq: CECE), today announced that Todd Gleason, Chief Executive Officer, and Matt Eckl, Chief Financial Officer, will participate in the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 at 4:00 PM ET.

Key Points: 
  • DALLAS, Sept. 1, 2020 /PRNewswire/ -- CECO Environmental Corp. (Nasdaq: CECE), today announced that Todd Gleason, Chief Executive Officer, and Matt Eckl, Chief Financial Officer, will participate in the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 at 4:00 PM ET.
  • CECO's presentation can be accessed through the H.C. Wainwright conference portal for registered participants and in the investor relations section of the Company's website: www.cecoenviro/events.com .
  • CECO Environmental is a global leader in air quality and fluid handling serving the energy, industrial and other niche markets.
  • Providing innovative technology and application expertise, CECO helps companies grow their business with safe, clean and more efficient solutions that help protect our shared environment.

H.C. Wainwright & Co. Once Again Ranked #1 by PlacementTracker

Retrieved on: 
Thursday, February 6, 2020

As noted by PlacementTracker, H.C. Wainwright effectuated more than 3 times the number of transactions than any other firm in 2019.

Key Points: 
  • As noted by PlacementTracker, H.C. Wainwright effectuated more than 3 times the number of transactions than any other firm in 2019.
  • In addition to being the #1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct and Private Placement transactions, H.C. Wainwright executed over 200 transactions in 2019 totaling over $7.6 Billion in transaction value.
  • According to PlacementTracker, the H.C. Wainwright Team has been the #1 ranked Underwriter/Placement Agent by deal volume cumulatively since 1998.
  • H.C. Wainwright is a full-service Investment Bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions.